25

12000

Ø 001/019

PTQ/\$B/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a co ection of information unless it displays a valid OMB control number. Application Number 10/078,949 Filing Date TRANSMITTAL RECEIVED 2/20/2002 First Named Inventor GENTRAL FAX CENTER FORM Stanley T. Crooke Art Unit 1635 <u>SEP 2 5 2006</u> Examiner Name Sean McGarry (to be used for all correspondence after initial filing) Atlorney Docket Number ISIS-5027 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Fee Attached Appeal Communication to Board Licensing-related Papers of Appeals and Interferences **Preliminary Amendment** Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer **Extension of Time Request** below): Request for Refund Express Abandonment Request CD, Number of CD(s) information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Isis Pharmaceuticals, Inc. Signature Printed name Connolly, Ph.D. Jodi Date Reg. No. 54,044 DO 10 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of Information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on amount of time you require to complete this farm and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce. P.O. Box 1450, Alexandria, VA 22315-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 and select option 2.

Laura Eames

Typed or printed name

APPLICANTS: Stanley T. Crooke

SERIAL NO: 10/078,949

Docket No.: ISIS-5027

DOCKET NO: ISIS-5027

→ PATENT OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Customer No.: 32650

阿利亞與斯里 SEP 2 5 2006

Applicant:

Stanley T. Crooke

Confirmation No.:

8454

Serial No.:

10/078,949

Group Art Unit:

1635

Filed:

February 20, 2002

Examiner:

Sean McGarry

Title: OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA

> I certify that this correspondence is being facsimile transmitted or is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

On September 25, 2006

aura Eames

MS Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Examiner:

AMENDMENT AND REQUEST FOR RECONSIDERATION

In response to the Office Action dated June 23, 2006, reconsideration is respectfully requested in view of the following amendments and/or remarks.

Amendments to the Specification begin on page 2.

Amendments to the Claims are reflected in the listing of claims which begins on page 6.

Remarks begin on page 14.